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Abstract Stimulation of monocytes/macrophages with lipo-
polysaccharide (LPS) results in activation of nuclear factor-UB
(NF-UB), which plays crucial roles in regulating expression of
many genes involved in the subsequent inflammatory responses.
Here, we investigated roles of transforming growth factor-L
activated kinase 1 (TGF-TAK1), a mitogen-activated protein
kinase kinase kinase (MAPKKK), in the LPS-induced signaling
cascade. A kinase-negative mutant of TAK1 inhibited the LPS-
induced NF-UB activation both in a macrophage-like cell line,
RAW 264.7, and in human embryonic kidney 293 cells
expressing toll-like receptor 2 or 4. Furthermore, we demon-
strated that endogenous TAK1 is phosphorylated upon simula-
tion of RAW 264.7 cells with LPS. These results indicate that
TAK1 functions as a critical mediator in the LPS-induced
signaling pathway.
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Key words: Lipopolysaccharide; TAK1; Toll-like receptor;
Nuclear factor-UB; Macrophage; Innate immunity
1. Introduction
In innate immunity of mammal, monocytes/macrophages
play key roles in detection and elimination of pathogens.
These types of cells are activated by microorganism-derived
molecules such as lipopolysaccharide (LPS), peptidoglycan, or
lipoteichoic acid. LPS, also called endotoxin, a major compo-
nent of the outer cell wall of Gram-negative bacteria, is one of
the strongest activator for monocytes/macrophages [1]. The
activated macrophages secrete chemical mediators including
proin£ammatory cytokines, chemokines and reactive oxygen
species, which, in concert, lead to in£ammation and the acti-
vation of adaptive immunity e¡ective to eliminate microor-
ganisms. On the other hand, uncontrolled activation of mac-
rophages by severe infections of Gram-negative bacteria
causes life-threatening septic-shock via overproduction of
the cytokines, including tumor necrosis factor (TNF)-K, inter-
leukin (IL)-1, -6 or -8 [2].
Upon infection of Gram-negative bacteria, LPS forms a
complex with LPS-binding protein (LBP) in plasma, and is
then transferred to CD14, a cell surface antigen of mono-
cytes/macrophages [3,4]. In the LPS-stimulated macrophages,
activated are two important intracellular proteins, the tran-
scription factor nuclear factor-UB (NF-UB) [5] and p38 mito-
gen-activated protein kinase (MAP kinase) [6]. NF-UB is acti-
vated by degradation of its cytoplasmic inhibitor, IUB-K or
IUB-L, induced by phosphorylation catalyzed by IUB-kinase
(IKK)-K and -L [7]. The activated NF-UB regulates transcrip-
tion of many cytokines, chemokines, nitric oxide synthase,
cell adhesion molecules and co-stimulatory ligands such as
B7.1 [8,9]. p38 is also activated by phosphorylation by MAP
kinase kinase. Although precise roles of p38 in the cytokine
production are not yet known, a speci¢c inhibitor for p38,
SB203580, was shown to inhibit tumor necrosis factor-K
(TNF-K) or IL-1 production in LPS-stimulated macrophages
[10].
Although CD14 was shown to be critical for LPS recogni-
tion on the cell surface, other protein(s) that transduce LPS-
signaling across the plasma membrane has been postulated
since CD14 is a glycosylphosphatidylinositol (GPI)-anchored
membrane protein without a cytoplasmic domain. Recently
several reports showed that two human homologues of the
membrane receptor toll of Drosophila, toll-like receptors
(TLR) 2 and 4, are candidates for such a signal transducer(s)
on the membrane. When transfected in LPS-unresponsive
cells, TLR2 was capable of mediating the activation of NF-
UB upon LPS stimulation [11,12]. Moreover it has been dem-
onstrated that two strains of LPS-hyporesponder mice, C3H/
HeJ and C57BL/10ScCr, have defects in their genes for TLR4
[13,14]. It was also shown that TLR4-knockout mice lose
sensitivity to LPS [15].
Since cytoplasmic domains of TLRs are homologous to
that of IL-1 receptor, similarities in their intracellular signal-
ing pathways through these receptors are suggested [16,17].
Recently, transforming growth factor (TGF)-L activated ki-
nase 1 (TAK1), which was originally identi¢ed as a member of
MAP kinase kinase kinase (MAPKKK) family mediating
TGF-L signaling, has been shown to be involved in the IL-
1-induced activation of NF-UB and c-Jun NH2-terminal pro-
tein kinase (JNK) [18,19]. In the present study, we explored
the involvement of TAK1 in the LPS-mediated NF-UB
activation. Our results demonstrated that TAK1 is phos-
phorylated concomitant with its activation in LPS-stimulated
macrophages and its activity was necessary for the activation
of NF-UB. Thus, TAK1 plays critical roles in the LPS-medi-
ated cellular activation leading to the subsequent in£amma-
tion.
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2. Materials and methods
2.1. Plasmids
cDNAs for full-length human TAK1, human TNF receptor-associ-
ated factor 6 (TRAF6) and mouse MyD88 were obtained by reverse
transcription-polymerase chain reaction (RT-PCR) with RNA of
THP-1 cells or RAW 264.7 cells as a template. cDNAs for human
TLR2 and TLR4 were ampli¢ed from cDNA derived from human
leukocyte (Clontech Laboratories, Palo Alto, CA, USA). Obtained
cDNAs were subcloned into pcDNA3 (Invitrogen, Carlsbad, CA,
USA) with an NH2-terminal Flag or Myc epitope. A dominant neg-
ative mutant TAK1(K63W) and a truncated MyD88 mutant (MyD88-
N: amino acids 1^151) were created by a polymerase chain reaction-
mediated mutagenesis. The sequences were con¢rmed by dideoxy se-
quencing. An expression vector for Flag-tagged full-length human
NF-UB-inducing kinase (NIK) was kindly provided by Dr. D. Wal-
lach. An NF-UB-luciferase reporter plasmid, pELAM1-Luc, was con-
structed by inserting a fragment of 3730 to +52 of E-selectin gene
into pGL3-Basic (Promega, Madison, WI, USA). As an internal con-
trol reporter, the plasmid pRL-TK (Promega) containing Renilla lu-
ciferase cDNA was used.
2.2. Cell culture and reagents
Human embryonic kidney (HEK) 293 cells were kindly provided by
Dr. F. Tokunaga and RAW 264.7 cells, a murine macrophage-like cell
line, were obtained from Dainippon, Osaka, Japan. RAW 264.7 cells
and HEK 293 cells were maintained in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% heat-inactivated fetal calf serum
(BioWhittaker, Walkersville, MD, USA), 100 U/ml penicillin, and
100 Wg/ml streptomycin at 37‡C in 5% CO2. LPS from Escherichia
coli 0111:B4 was purchased from List Biological Laboratories, Camp-
bell, CA, USA.
2.3. Transfection
RAW 264.7 cells were transfected with expression plasmids using
FuGENE6 Transfection Reagent according to the manufacturer’s in-
structions (Roche Diagnostics, Indianapolis, IN, USA). HEK 293
cells were transfected by the calcium phosphate method as described
previously [20].
2.4. Luciferase assay
Cells were transiently transfected with pELAM1-Luc and pRL-TK
together with indicated plasmids. The total amount of DNA was kept
constant with empty vector for each transfection. 48 h after trans-
fection, cells were stimulated with LPS at 37‡C for 6 h. Cells were
then lysed, and their luciferase activities were measured by using the
Dual-Luciferase Reporter system (Promega).
2.5. Detection of phosphorylated TAK1
RAW 264.7 cells were incubated with or without 1 Wg/ml LPS at
37‡C for the indicated time and then lysed in lysis bu¡er containing
50 mM Tris^HCl (pH 7.5), 0.15 M NaCl, 1% NP-40, 2 mM EDTA,
50 mM NaF, 0.2 mM Na3VO4 and 2 Wg/ml aprotinin. The lysate was
divided into half and immunoprecipitated with anti-TAK1 polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). One of
the immunoprecipitates was treated with 400 units of lambda protein
phosphatase (New England Biolabs, Beverly, MA, USA) at 30‡C for
30 min and the other was left untreated. The immunoprecipitates were
subjected to 7.5% sodium dodecylsulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) followed by immunoblotting with the same
antibody.
3. Results and discussion
3.1. TAK1 is required for the LPS-induced NF-UB activation
A recent report by Ninomiya-Tsuji et al. showed that
TAK1 is activated by the stimulation of IL-1 and is required
for the activation of NF-UB [19]. Since IL-1 receptor and
TLRs have homologous cytoplasmic domains and several
common intracellular signaling molecules, such as MyD88
and IL-1 receptor-associated kinase (IRAK), were shown to
be involved both in the IL-1- and the LPS-signaling [16,17,21^
24], we investigated whether TAK1 also participates in the
signaling pathway induced by LPS.
We constructed an expression vector for a kinase-negative
mutant of TAK1 carrying a single amino acid substitution
(Lys-63 to Trp) [18,19] and analyzed the e¡ects of expression
of the mutant form of TAK1 on the activation of NF-UB in a
mouse macrophage-like cell line, RAW 264.7. RAW 264.7
cells transfected with an NF-UB reporter showed strong acti-
vation of NF-UB 6 h after the LPS stimulation (Fig. 1). We
then transfected the wild type and the mutant form of TAK1
into the cells and examined the NF-UB activity with or with-
out the LPS stimulation. Without the simulation, both the
wild and mutant TAK1 did not a¡ect the basal NF-UB activ-
ity. On the other hand, the mutant form of TAK1 inhibited
the LPS-induced activation of NF-UB in a dose-dependent
manner, whereas expression of the wild type TAK1 exhibited
marginal e¡ects. Thus, the kinase activity of TAK1 is required
for the LPS-induced signaling pathway leading to the activa-
tion of NF-UB in macrophages.
3.2. TAK1 is phosphorylated upon LPS stimulation
The previous report showed that TAK1 is activated on the
stimulation by IL-1 [19]. Since there is no report that exam-
ined TAK1 activation in LPS stimulated cells, we investigated
Fig. 1. E¡ects of the mutant TAK1 on the LPS-induced NF-UB ac-
tivation. RAW 264.7 cells were transfected with an expression vec-
tor for the mutant TAK1 (TAK1 K63W; 0.1, 0.4, and 0.7 Wg) or
the wild type TAK1 (TAK1 wt; 0.1 and 0.7 Wg) together with re-
porter plasmids. 48 h after transfection, the transfected cells were
stimulated with or without 100 ng/ml LPS at 37‡C for 6 h. Then
the cells were lysed and luciferase activities were measured. Activity
of the NF-UB reporter was normalized on the basis of Renilla lucif-
erase activity. Data shown are the mean þ S.E.M. of two indepen-
dent transfections. A representative result of two separate experi-
ments is shown.
Fig. 2. Phosphorylation of TAK1 by LPS stimulation. RAW 264.7
cells were stimulated with 1 Wg/ml LPS at 37‡C for the indicated
time. Then the cells were lysed and endogenous TAK1 was immu-
noprecipitated with anti-TAK1 antibody. Equal amounts of the im-
munoprecipitates were treated (+) or untreated (3) with protein
phosphatase (PPase) and TAK1 was visualized by immunoblotting.
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activation of TAK1 in the macrophage-like cell line in which
the NF-UB activity is strongly induced by LPS.
When TAK1 is activated, it is phosphorylated and the
phosphorylation correlates well with the kinase activity
[19,25]. Accordingly, we analyzed phosphorylation of TAK1
by the LPS stimulation. RAW 264.7 cells were incubated with
1 Wg/ml LPS for the indicated time and then endogenous
TAK1 was visualized by immunoprecipitation followed by
immunoblotting with anti-TAK1 antibody. On 7.5% SDS^
PAGE, TAK1 in the stimulated cells reproducibly showed
slightly slower mobility than in the resting cells (Fig. 2). Treat-
ment of the TAK1 immunoprecipitate with protein phospha-
tase abolished the mobility shift, indicating that the shift is
caused by phosphorylation. Phosphorylation of TAK1 is evi-
dent at 10 min after the stimulation and continued at least for
1 h.
We have also tried in vitro kinase assay of TAK1 by using
MKK6 as a substrate. Unfortunately, we failed to detect the
increased kinase activity of TAK1 even in the IL-1-treated 293
cells. In the previous report [19], they used 293 cells stably
transfected with IL-1 receptor; therefore the cells are strongly
stimulated by IL-1. Since immunoprecipitated TAK1 is auto-
phosphorylated and activated rapidly in vitro when incubated
in the presence of ATP during kinase assay, it would be di⁄-
cult to detect the activation by kinase assay in normal cells.
TRAF6 was reported to be associated with TAK1 on the
stimulation with IL-1 [19]. In our preliminary experiment,
however, we failed to detect TRAF6 in the TAK1 immuno-
precipitates from the LPS-stimulated cells. TAK1 has also
been reported to be required for the NF-UB activation by
the TNF-K stimulation [25]. Since the TNF-K signaling uti-
lizes TRAF2 but not TRAF6 [26,27], and TAK1 does not
associate with TRAF2 [19], the association of TAK1 with
TRAF6 might not be essential for the phosphorylation and
activation of TAK1 in the TNF-K- and/or LPS-signaling.
3.3. TAK1 participates in the NF-UB activation by the LPS
stimulation through TLR2 and 4
The results shown in Figs. 1 and 2 indicated that TAK1 is
activated and is required for the LPS-induced NF-UB activa-
tion in a macrophage-like cell line. Since TLR2 and/or 4 is
involved in the LPS signaling [11^15], we next used HEK 293
cells transiently transfected by cDNAs for TLR2 and 4 to
analyze the TLR-dependent LPS signaling pathway.
Several groups reported that TLR4-transfected HEK 293
cells showed constitutive activation of NF-UB and were not
responsive to LPS [11,12,28]. In our experimental system,
however, TLR4-transfected HEK 293 cells exhibited the acti-
Fig. 3. E¡ects of the mutant TAK1 on the LPS-induced NF-UB ac-
tivation in TLR-transfected HEK 293 cells. HEK 293 cells were
transfected with an empty vector or an expression vector for TLR2
or TLR4 together with reporter plasmids (A). In B and C, the same
cells were transfected with an expression vector for the kinase-nega-
tive TAK1 (TAK1 K63W; 0.1, 0.5, 1.0 Wg) or the wild type TAK1
(TAK1 wt; 0.1, 1.0 Wg) together with reporter plasmids and an ex-
pression vector for TLR2 (B) or TLR4 (C), respectively. 48 h after
transfection, cells were stimulated with or without 1 Wg/ml LPS at
37‡C for 6 h. Then the cells were lysed and luciferase activities were
measured. Activity of the NF-UB reporter was normalized on the
basis of Renilla luciferase activity. Data shown are the mean þ
S.E.M. of two independent transfections. A representative result of
at least two separate experiments is shown.
Fig. 4. E¡ects of the mutant TAK1 mutant on the MyD88-,
TRAF6- and NIK-induced NF-UB activation. HEK 293 cells were
transfected with an expression vector for MyD88-N, TRAF6 or
NIK (0.65 Wg), respectively and empty vector or the kinase-negative
mutant of TAK1 (TAK1 K63W; 1 Wg) together with reporter plas-
mids. 48 h after transfection, cells were lysed and luciferase activities
were measured. Activity of the NF-UB reporter was normalized on
the basis of Renilla luciferase activity. The NF-UB activity was rep-
resented as percent of the activities of the cells transfected with
MyD88-N, TRAF6, and NIK with empty vector, respectively. Data
shown are the mean þ S.E.M. of two independent transfections. A
representative result of two separate experiments is shown.
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vation of NF-UB reporter activity upon stimulation with 1 Wg/
ml LPS as well as TLR2-transfected cells, in the presence of
fetal calf serum as a source of soluble form of CD14. The
possible reason for this apparent discrepancy will be described
elsewhere (T.M., unpublished). Mock-transfected HEK 293
cells did not respond to LPS (Fig. 3A). We co-transfected
the kinase-negative form of TAK1 (K63W) into these cells
to examine its e¡ects on the LPS-mediated activation of
NF-UB. Whereas the wild type TAK1 was without e¡ects,
expression of the kinase-negative mutant of TAK1 dose-de-
pendently inhibited the LPS-mediated NF-UB activation both
in the TLR2- and TLR4-expressing cells (Fig. 3B,C). The
results indicate that TAK1 is required for the TLRs-mediated
activation of NF-UB by LPS.
Compared with the results on TLR2/4-transfected HEK 293
cells, the expression of the mutant TAK1 in RAW 264.7 cells
was less e¡ective in inhibiting the NF-UB activation. It re-
mains to be determined if this is due to low transfection e⁄-
ciency or existence of other LPS-signaling pathways indepen-
dent of TLR2/4 in macrophages. It is to be noted that
dominant negative mutants for MyD88, IRAK and TRAF6
only partially inhibited the LPS-induced NF-UB activation
(V50%) in human monocytic THP-1 cells [24].
3.4. TAK1 acts downstream of MyD88 and TRAF6 and
upstream of NIK
In order to dissect the TAK1-mediated LPS signaling path-
way, we co-expressed the TAK1 mutant with several consti-
tutive active signaling molecules. We transfected cDNAs for
an N-terminal portion of MyD88, full-length TRAF6 or NIK
into HEK 293 cells together with the NF-UB reporter [27,29^
31]. As expected, the NF-UB activities were activated in these
cells without stimulation (Fig. 4). We then co-transfected
empty vector or the dominant negative form of TAK1
cDNA with each constitutively active molecule. In contrast
to empty vector, co-expression of the kinase-negative TAK1
functioned as a dominant negative mutant, inhibiting the NF-
UB activity induced by the expression of MyD88 and TRAF6.
The results indicate that TAK1 functions downstream of
MyD88 and TRAF6 as in the IL-1 signaling (Fig. 4) [19].
On the other hand, the TAK1 mutant exhibited marginal
e¡ects on the NF-UB activity induced by NIK, suggesting
that TAK1 is most likely to transduce signals upstream of
NIK, which then activates IKKK/L. This is con¢rmed by
the ¢nding that the activation of NF-UB by co-expressing
TAK1 and TAB1 is inhibited by expression of dominant neg-
ative mutants of NIK [19,25].
In conclusion, TAK1 is activated by phosphorylation in the
LPS stimulated macrophages via TLR2 and/or 4-mediated
pathway, whose kinase activity is required for the NF-UB
activation. TAK1 regulates NIK activity that activates
IKKK/L downstream of MyD88 and TRAF6. TAK1 is also
known to be a MAP kinase kinase kinase for p38 [32] and the
activity of p38 is critical for the production of proin£amma-
tory cytokines by activated monocytes/macrophages [10].
Therefore, TAK1 is one of the key enzymes for the regulation
of the activation of these cells in the innate immunity.
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